Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ESRRG | P62508 | 3/20 | 0.52 |
| ▸ | TYR | P14679 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637766 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP3A4ESRRGTYR | |
| SCHEMBL5172480 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP3A4ESRRGTYR | |
| Lactic Acid SCHEMBL28390780 | 0.89 | ESR2 (0.42) | ESR1ESR2CYP3A4ESRRGTYR | |
| 4-Hydroxyphenylpyruvic Acid SCHEMBL14717758 | 0.83 | FNTA (0.50) | ESR1ESR2CYP3A4ESRRGALDH1A1 | |
| SCHEMBL4327309 | 0.82 | ESR1 (0.52) | ESR1ESR2CYP3A4ESRRGTYR | |
| SCHEMBL30927966 | 0.82 | TSHR (0.48) | LMNATSHRALDH1A1CA2CYP2D6 | |
| SCHEMBL7866065 | 0.82 | TSHR (0.48) | LMNATSHRALDH1A1CA2CYP2D6 | |
| SCHEMBL21557850 | 0.81 | MAPT (0.52) | ESR1ESR2CYP3A4ARALDH1A1 | |
| SCHEMBL197251 | 0.81 | MAPT (0.52) | ESR1ESR2CYP3A4ARALDH1A1 | |
| SCHEMBL4326795 | 0.81 | MAPT (0.52) | ESR1ESR2CYP3A4ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1094 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260123658-A1 | Methods of Increasing the Beneficial Properties of Fermented Foods | The Brd. of Trustees of the Univ. of Illinois (US) | 2026-05-07 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| WO-2025133394-A1 | METABOLIC FINGERPRINTING OF SALIVA SAMPLES USING NMR | MAVEN HEALTH GMBH (CH) | 2025-06-26 | — | — | WO | claimed |
| CN-120048503-A | Preeclampsia risk assessment prediction model based on metabonomics and application thereof | 深圳华大基因股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-120048502-A | Multi-parameter preeclampsia risk assessment prediction model and application thereof | 深圳华大基因股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-120026047-A | Microorganism with restructured aromatic amino acid metabolic pathway, construction method and application thereof | 中国科学院青岛生物能源与过程研究所 | 2025-05-23 | — | — | CN | claimed |
| US-20250163356-A1 | SYSTEMS AND METHODS FOR REJUVENATING CELL CULTURE MEDIUM | FUTURE MEAT TECHNOLOGIES LTD. (IL) | 2025-05-22 | — | — | US | claimed |
| CN-119985745-A | Detection method for micromolecular phenolic substances and application thereof | 北京中医药大学 | 2025-05-13 | — | — | CN | claimed |
| CN-117695202-B | Probiotic metazoan composition for improving scalp environment and preparation method and application thereof | 金华银河生物科技有限公司 | 2025-05-02 | — | — | CN | claimed |
| EP-1470099-A1 | PROCESS FOR PURIYING AN ORGANIC ACID | A.E. STALEY MANUFACTURING COMPANY (US) | 2004-10-27 | — | — | EP | claimed |
| US-20030180772-A1 | Detection of DNA damage | DIONEX CORPORATION | 2003-09-25 | — | — | US | claimed |
| US-20030180771-A1 | Electrochemically analyzing samples from selected areas of the body of living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage | DIONEX CORPORATION | 2003-09-25 | — | — | US | claimed |
| US-20030171615-A1 | Process for purifying an organic acid | TATE & LYLE INGREDIENTS AMERICAS, INC. | 2003-09-11 | — | — | US | claimed |
| WO-2003059863-A1 | PROCESS FOR PURIYING AN ORGANIC ACID | A.E. STALEY MANUFACTURING CO. (US) | 2003-07-24 | — | — | WO | claimed |
| US-6548252-B1 | Electrochemically analyzing samples from selected areas of the body of a living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage | ESA, INC. | 2003-04-15 | — | — | US | claimed |
| EP-1223215-A1 | TRANSFORMANT PRODUCING SECONDARY METABOLITE MODIFIED WITH FUNCTIONAL GROUP AND NOVEL BIOSYNTHESIS GENES | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-17 | — | — | EP | claimed |
| US-6043058-A | Preparation of cyclic depsipeptide compounds and a novel cyclic depsipeptide | MAIJI SEIKA KAISHA LTD. (JP) | 2000-03-28 | — | — | US | claimed |
| EP-0930304-A1 | PROCESS FOR PRODUCING CYCLODEPSIPEPTIDE COMPOUNDS AND NOVEL CYCLODEPSIPEPTIDE | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-07-21 | — | — | EP | claimed |
| EP-0374184-B1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE MEDICINE (US) | 1994-01-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260123658-A1 | Methods of Increasing the Beneficial Properties of Fermented Foods | AADAT, IDO1, ALDOA | ESR1 3952/4885ESR2 4145/4885CYP3A4 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.